Murat Sezer
Overview
Explore the profile of Murat Sezer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tas A, Bayhan M, Yildiz M, Alan Y, Atay Z, Sezer F, et al.
Appl Neuropsychol Adult
. 2025 Feb;
:1-10.
PMID: 39992094
Introduction: Flow velocity acceleration pattern is related to shear stress, pressure changes, cardiovascular risk factors, diabetes mellitus, hypertension, endothelial dysfunction and arterial stiffness. Considering the hemodynamic alterations in cognitive impairment,...
2.
Tas A, Alan Y, Muftuogullari A, Haj Mohammad A, Umman S, Parker K, et al.
Microvasc Res
. 2024 Oct;
157:104750.
PMID: 39357645
Coronary microvascular vasodilator capacity is substantially associated with coronary pressure waveform and dicrotic notch morphology, with or without concomitant epicardial disease. A prominent dicrotic notch is associated with preserved microvascular...
3.
Bugra Z, Emet S, Umman B, Karaca Ozer P, Sezer M, Baykiz D, et al.
Am Heart J Plus
. 2024 Apr;
13:100081.
PMID: 38560087
Objective: The aim of this cross-sectional, retrospective, descriptive study was to review and classify cardiac masses systematically and to determine their frequencies. Methods: The medical records of 64,862 consecutive patients...
4.
Cevik E, Tas A, Demirtakan Z, Damman P, Alan Y, Broyd C, et al.
Am Heart J
. 2024 Jan;
270:62-74.
PMID: 38278503
Background: Coronary microvascular dysfunction (CMD) is the leading cause of ischemia with no obstructive coronary arteries disease (INOCA) disease. Diagnosis of CMD relies on surrogate physiological indices without objective proof...
5.
Hasdemir H, Tas A, Cevik E, Alan Y, Broyd C, Ozcan A, et al.
Open Heart
. 2023 Nov;
10(2).
PMID: 38011991
Background: Although there are studies examining each one separately, there are no data in the literature comparing the magnitudes of the iatrogenic, percutaneous coronary intervention (PCI)-induced, microvascular dysfunction (Type-4 CMD)...
6.
Sezer M, Tas A, Demirtakan Z, Broyd C, Ozcan A, Hasdemir H, et al.
Microvasc Res
. 2023 Feb;
147:104495.
PMID: 36739961
Background: There is an ongoing debate on the extension of reperfusion-related microvascular damage (MVD) throughout the remote noninfarcted myocardial regions in patients with ST-elevation myocardial infarction (STEMI) that undergo primary...
7.
Tas A, Alan Y, Bayhan M, Atay Z, Citak H, Sezer F, et al.
J Diabetes Sci Technol
. 2022 Nov;
17(2):595-597.
PMID: 36426624
No abstract available.
8.
Sezer M, Escaned J, Broyd C, Umman B, Bugra Z, Ozcan I, et al.
J Am Heart Assoc
. 2022 May;
11(10):e024172.
PMID: 35574948
Background Intramyocardial edema and hemorrhage are key pathological mechanisms in the development of reperfusion-related microvascular damage in ST-segment-elevation myocardial infarction. These processes may be facilitated by abrupt restoration of intracoronary...
9.
Sezer M, Aslanger E, Cakir O, Atici A, Sezer I, Ozcan A, et al.
Cardiology
. 2020 Aug;
146(1):1-10.
PMID: 32846410
Fractional flow reserve (FFR) may not be immune from hemodynamic perturbations caused by both vessel and lesion related factors. The aim of this study was to investigate the impact of...
10.
Uludag O, Bektas M, Cene E, Sezer M, Sahinkaya Y, Gul A, et al.
J Thromb Thrombolysis
. 2020 Jun;
51(2):466-474.
PMID: 32588289
The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective...